AU2018224391B2 - CXCR2 antibodies and uses thereof - Google Patents

CXCR2 antibodies and uses thereof Download PDF

Info

Publication number
AU2018224391B2
AU2018224391B2 AU2018224391A AU2018224391A AU2018224391B2 AU 2018224391 B2 AU2018224391 B2 AU 2018224391B2 AU 2018224391 A AU2018224391 A AU 2018224391A AU 2018224391 A AU2018224391 A AU 2018224391A AU 2018224391 B2 AU2018224391 B2 AU 2018224391B2
Authority
AU
Australia
Prior art keywords
seq
set forth
antibody
cxcr2
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018224391A
Other languages
English (en)
Other versions
AU2018224391A1 (en
Inventor
Charles Reay Mackay
Remy Michel ROBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900656A external-priority patent/AU2017900656A0/en
Application filed by Monash University filed Critical Monash University
Publication of AU2018224391A1 publication Critical patent/AU2018224391A1/en
Application granted granted Critical
Publication of AU2018224391B2 publication Critical patent/AU2018224391B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018224391A 2017-02-27 2018-02-27 CXCR2 antibodies and uses thereof Active AU2018224391B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900656 2017-02-27
AU2017900656A AU2017900656A0 (en) 2017-02-27 CXCR2 antibodies
PCT/IB2018/000253 WO2018154391A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2018224391A1 AU2018224391A1 (en) 2019-09-19
AU2018224391B2 true AU2018224391B2 (en) 2025-06-12

Family

ID=63253562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018224391A Active AU2018224391B2 (en) 2017-02-27 2018-02-27 CXCR2 antibodies and uses thereof

Country Status (8)

Country Link
US (1) US11053319B2 (enExample)
EP (1) EP3585816A4 (enExample)
JP (2) JP7562258B2 (enExample)
KR (1) KR102673489B1 (enExample)
CN (1) CN110637034B (enExample)
AU (1) AU2018224391B2 (enExample)
CA (1) CA3054616A1 (enExample)
WO (1) WO2018154391A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES
EP3830124A1 (en) 2018-08-01 2021-06-09 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
JP7673981B2 (ja) * 2019-09-04 2025-05-09 シャンハイテック ユニバーシティ 抗ｃｘｃｒ２抗体およびその使用
US20240166756A1 (en) * 2021-04-26 2024-05-23 Kaohsiung Medical University Anti-CXCR2 Antibodies and Uses Thereof
KR20250001497A (ko) * 2023-06-28 2025-01-07 (재) 스크립스코리아항체연구원 항-cxcr2 항체 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
WO2012062713A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
WO2013168108A2 (en) * 2012-05-09 2013-11-14 Novartis Ag Chemokine receptor binding polypeptides
WO2014170317A1 (en) * 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2015169811A2 (en) * 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
WO2012062713A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
WO2013168108A2 (en) * 2012-05-09 2013-11-14 Novartis Ag Chemokine receptor binding polypeptides
WO2014170317A1 (en) * 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2015169811A2 (en) * 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOSHUIZEN R. S. ET AL.: "A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2", MABS, vol. 6, no. 6, 2014, pages 1415 - 1424, XP055558502 *

Also Published As

Publication number Publication date
JP2020508074A (ja) 2020-03-19
EP3585816A1 (en) 2020-01-01
JP2023052023A (ja) 2023-04-11
CN110637034B (zh) 2023-10-10
CA3054616A1 (en) 2018-08-30
CN110637034A (zh) 2019-12-31
WO2018154391A1 (en) 2018-08-30
JP7562258B2 (ja) 2024-10-07
US20190016809A1 (en) 2019-01-17
US11053319B2 (en) 2021-07-06
AU2018224391A1 (en) 2019-09-19
KR20190123753A (ko) 2019-11-01
KR102673489B1 (ko) 2024-06-07
EP3585816A4 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US20220389114A1 (en) Pd-l1 antibodies binding canine pd-l1
KR102497259B1 (ko) Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
CN114805575B (zh) 人源化抗cd73抗体
CN107921122B (zh) 与cd38结合的抗体治疗剂
AU2018224391B2 (en) CXCR2 antibodies and uses thereof
KR20120089346A (ko) 높은 차단 활성을 갖는 항-Ｃ5ａ 결합 부분
US20190055313A1 (en) Antibodies against g-csfr and uses thereof
EP3464354B1 (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses
US10696741B2 (en) Anti-IL-22R antibodies
AU2021223063A1 (en) Anti-IL-2 antibody, and antigen-binding fragment thereof and medical use thereof
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
HK40006912B (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses
HK40006912A (en) Antibodies that bind to human anti-müllerian hormone (amh) and their uses
HK1253584B (zh) 与cd38结合的抗体治疗剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)